NEWS

Neurosteer’s Breakthrough hdrEEG™ Reimagines EEG with Its Better, Faster Approach to Analyzing the Brain

Thu, 15 Aug 2024 16:47:51 GMT

Neurosteer’s Breakthrough hdrEEG™ Reimagines EEG with Its Better, Faster Approach to Analyzing the Brain

NEW YORK, August 15, 2024 -- Under the direction of signal processing expert Nathan Intrator, PhD, Neurosteer’s team has created an affordable and accessible device that measures minute electrical brain activity. Their device can help patients and providers manage brain conditions more effectively and proactively.

MORE INFO

StartUp Health Selects Neurosteer to Join Alzheimer’s Moonshot Community

Tue, 21 May 2024 19:13:27 GMT

StartUp Health Selects Neurosteer to Join Alzheimer’s Moonshot Community

NEW YORK, May 21, 2024 -- Neurosteer has been selected into a small group out of 100+ companies that were identified as key players in the detection and treatment of Alzheimer’s. The Alzheimer’s Moonshot initiative is backed by $100M from Gates, Bezos, Lauder, the Dolby Foundation, and the Alzheimer's Drug Discovery Foundation (ADDF).

MORE INFO

Neurosteer’s Peer-Reviewed Publication: Evaluation of Parkinson’s Disease Early Diagnosis with Neurosteer’s hdrEEG™ System

Tue, 19 Dec 2023 18:09:08 GMT

Neurosteer’s Peer-Reviewed Publication: Evaluation of Parkinson’s Disease Early Diagnosis with Neurosteer’s hdrEEG™ System

NEW YORK, Dec. 19, 2023 -- Neurosteer Inc. announces the publication of our groundbreaking paper in Frontiers in Neurology detailing a revolutionary approach to Parkinson's disease detection and differentiation using our pocket-sized hdrEEG™ system and a rapid 15-minute auditory assessment.disorders.

The study was performed using Neurosteer’s FDA cleared medical-grade hdrEEG™ system which represents a breakthrough in brain “scanning” and offers a completely novel approach to analyzing brain activity.

The system is designed to support early detection and differentiation of neurodegenerative disorders and continuous brain monitoring in the ICU.disorders.

Neurosteer’s wireless, pocket-sized, medical-grade wearable device, with its innovative forehead-attached electrode adhesive strip, can be used anywhere. It is low cost, massively deployable, automatic and objective.

In conjunction with the device, our noninvasive, 15-minute auditory brain health assessment was used in the study for the detection of Parkinson's disease.

Paired with our cloud-based signal processing server, our system showed excellent correlation to F-DOPA PET scans in detecting and differentiating Parkinson’s disease, for a fraction of the cost, in a simple to operate, noninvasive, 15 minute procedure that can be performed virtually anywhere.

By contrast, today’s Parkinson’s disease assessments using F-DOPA PET scanners are invasive, cumbersome, and extremely expensive, and require a dedicated facility and subjective interpretation by clinicians. As a result, they are only performed after the onset of symptoms, by which time it may be too late for effective treatment.

Preliminary data suggests similar promise for Alzheimer’s disease, making it ideal for patient screening to benefit from recent Alzheimer’s drugs.

The company intends to establish a new standard of care in brain assessment and revolutionize early detection of Parkinson’s, Alzheimer’s and other neurodegenerative disorders.

MORE INFO

Neurosteer to Present at ApplySci MIT

Fri, 01 Sep 2023 20:07:15 GMT

Neurosteer to Present at ApplySci MIT | 2023

NEW YORK, Sep. 1, 2023 -- Neurosteer founder and CEO, Nathan Intrator PhD, has been invited to be a main speaker at the ApplySci AI + Deep Tech + NeuroTech conference at MIT later this month.

On September 18 at 11:30am, Intrator will demonstrate Neurosteer’s breakthrough hdrEEG™ technology in support of his presentation titled “Brain Wellness and Very Early Detection of Neurodegeneration.”

This will be the first time the company presents its connectivity analysis, which has historically been performed by an fMRI. But unlike the room-sized fMRI scanner, Neurosteer’s low-cost hdrEEG system uses just a wireless, wearable, pocket-sized device in conjunction with an innovative adhesive forehead dry-gel electrode strip.

And unlike an fMRI, which measures blood flow as an indirect proxy for brain activity, Neurosteer’s system directly measures electrical brain activity with much higher resolution, and then utilizes cloud-based signal processing to detect pathway connectivity changes that occur with different neurodegenerative disorders.

Intrator will describe the changes related to early Parkinson's and Alzheimer's, and how the company’s breakthrough technology can distinguish between different disorders.

MORE INFO

Brain Activity and Music as Seen with Neurosteer’s hdrEEG™ System

Tue, 20 Jun 2023 15:45:10 GMT

Brain Activity and Music as Seen with Neurosteer’s hdrEEG™ System

New York, Jun. 20, 2023 -- In “This Is What Music Does to Your Brain,” Yael Hallak of Haaretz writes that new research is exploring how to use music to bring people closer and even to diagnose cognitive decline in the elderly.

The article covers the work of Neurosteer’s Neta Maimon with music and brain activity. Maimon, a PhD and avid musician, has for years been championing the use of auditory stimulation for precise brain activation during the measurement of brain activity using Neurosteer’s hdrEEG™ system.

She was recently invited to New York to deliver a series of talks on her research.

“I’m truly honored to see my music cognition research, conducted at Neurosteer and the Buchmann-Mehta School of Music at Tel Aviv University, featured in Haaretz. A big thank you to Yael Hallak for perfectly connecting the dots between music, neuroscience, and cognition in her article,” said Maimon.

She continued: “Our research explores the profound influence music has on brain activity and cognitive functions – from managing stress and assessing cognitive load in musicians and medical surgeons to diagnosing cognitive decline and neurodegenerative disorders.”

Maimon has been instrumental in helping to develop Neurosteer’s auditory assessment tests.

MORE INFO

Neurosteer Announces FDA Clearance of the Neurosteer EEG Brain Monitoring Platform

Thu, 03 Nov 2022 16:56:52 GMT

Neurosteer’s EEG System Features Novel Brain Activity Representation Based on Advanced EEG Signal Processing Technology

NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Neurosteer Inc. today announced the FDA clearance of its Neurosteer® single-channel EEG brain monitoring platform. This clearance allows Neurosteer’s unobtrusive multi-purpose system to be used in a broad range of clinical settings. In the ICU, it can offer continuous brain monitoring to support critical interventions. In a doctor’s office, it can aid in the early detection of pre-symptomatic cognitive decline, including Alzheimer’s, Parkinson’s and dementia. And in pharma drug trials, it can assist in the rapid and cost-effective massive screening of subjects who may be suffering from neurodegenerative disorders.

Neurosteer advances the century-old EEG into the 21st century, using an adhesive electrode strip connected to a pocket-sized sensor that wirelessly transmits EEG data to the cloud for advanced signal processing. Using just a single adhesive forehead strip, Neurosteer’s innovative solution offers the traditional EEG frequency bands while also being cleared by the FDA to include several novel “brain metrics” visual representations.

These brain metrics rely on Neurosteer’s advanced signal processing technology and may assist trained medical staff in making neurological diagnoses. In addition, affixing the adhesive strip to the forehead avoids interference from the hair, and using dry gel supports unattended operation for up to 12 hours. Finally, the system includes a noninvasive assessment with auditory prompts that can aid in the early detection of brain deterioration.

Dr. Amitai Bickel, Surgeon at Western Galilee Hospital, commented, “After working with the Neurosteer EEG system for several years, I’ve realized what an advantage it is to have a compact, easy-to-apply EEG brain monitor that can be used for real-time continuous monitoring. Neurosteer’s innovative platform has the potential to revolutionize the standard of care in managing brain health.”

Dr. Nathan Intrator, Founder and CEO of Neurosteer, said, “We are extremely pleased that the FDA has cleared our portable and affordable EEG system, and moreover, recognized the potential clinical value of our brain metrics visual representations. This is an important step in achieving our goal of making brain monitoring and assessment widely available to all populations.”

About the Company

Neurosteer Inc. has developed an innovative brain monitoring platform that is based on a portable single-channel EEG. It uses an adhesive forehead electrode strip connected to a pocket-sized sensor that wirelessly transmits EEG data to the cloud for advanced signal processing. It complements traditional frequency band analysis with “brain metrics” visual representations. The company was founded in 2015 by Dr. Nathan Intrator to commercialize brain monitoring technology that he initially developed at Tel Aviv University. With offices in New York, California and Israel, the company’s patented product is currently being validated in clinical trials and used by pharmaceutical companies for patient screening and efficacy testing of new drugs.

MORE INFO

Neurosteer Delivers Real-Time Brain Monitoring to Peter Gabriel Reverberation Event

Sun, 23 Oct 2022 16:54:47 GMT

On October 23, 2022, Neurosteer participated in an event at the Fotografiska Museum in NYC.

The event was organized by Peter Gabriel (of Genesis fame) to celebrate the book launch of Reverberation: Do Everything Better with Music by Keith Blanchard. The book highlights specific songs and techniques to help you sleep better, be more productive, stimulate creative breakthroughs, have better sex, and more.

As part of the event, three participants – two drummers and a meditator – were fitted with a Neurosteer EEG brain monitor. As the drummers played music, Neurosteer demonstrated the effect of music and meditation on the brain using real-time graphics, displaying their brain activity as it related to the intensity of focus, relaxation, and emotion.

MORE INFO

Israeli Scientists Say Brain Analysis Tool Can Spot Cognitive Decline – Using Music

Fri, 26 Aug 2022 16:51:57 GMT

Doctors today rely on face-to-face questions and answers to diagnose cognitive decline, but new peer-reviewed research suggests music may help make EEG-based testing viable.

Israeli scientists say they have developed a warning system for cognitive decline, which works by tracking brain function as elderly people listen to music.

With a three-electrode pad attached to their heads, people undergoing the test are asked to complete tasks, such as pressing a button when a particular instrument plays.

The pad is attached to a machine, which monitors brain function. An algorithm analyses the data to determine whether or not the brain function suggests that cognitive decline is underway, and if so, to what extent.

A Tel Aviv University PhD student, Neta Maimon, came up with the new 15-minute test, which has been trialed on dozens of elderly people in newly peer-reviewed research. The same people also underwent testing using standard assessment for cognitive decline, and the results from both tests largely matched.

She believes that after further development, assessment and regulatory approval, the test could “improve the quality of life of millions around the world” by providing more accessible screening than today’s cognitive tests, which are labor-intensive for doctors and normally reserved for people who already have concerns. Largely automated, she said that hers could be used as a routine test.

Cognitive decline relates to difficulties, beyond what are typically expected in aging, in a person’s brain functions such as thinking, memory and concentration.

“Our method enables the monitoring of cognitive capability and detection of cognitive decline in the early stages. It could do so by simple and accessible means, with a quick and easy test that can be conducted in any clinic,” Maimon said.

“Screening tests are commonly accepted for a variety of physiological problems such as diabetes, high blood pressure and breast cancer. But to date, no method has yet been developed to enable routine, accessible monitoring of the brain for cognitive issues.”

The study took place at Tel Aviv University’s School of Psychological Sciences and the Buchmann-Mehta School of Music, under the supervision of Prof. Nathan Intrator from the Blavatnik School of Computer Science and the Sagol School of Neuroscience.

Doctors normally diagnose cognitive decline by a face-to-face assessment that involves questions and tasks. There is a more objective method, but it involves a painful and invasive procedure to remove spinal fluid for testing. There is significant research toward a noninvasive objective method, some of it focused on magnetic resonance imaging (MRI) or scalp electroencephalogram (EEG), but no such method is in widespread use today.

Maimon uses an EEG machine to analyze the electrical activity in the brain as people complete her music test. A combination of the brain activity patterns and data on how quickly people completed tasks, like the button press when a particular instrument plays, gives scientists a strong indication of cognitive status.

The test uses an unusually-compact Israeli-made EEG machine, produced by the Neurosteer startup, which is headed by Intrator. Maimon says using a portable device makes her approach viable for mobile testing in elderly homes and clinics.

Maimon said that the approach needs further development and assessment, but could hold great potential.

“Today, millions of people around the world already suffer or are liable to suffer soon from cognitive decline and its dire consequences, and their number will only increase in the coming decades,” she said.

“Our method could pave the way towards efficient cognitive monitoring of the general population, and thus detect cognitive decline in its early stages, when treatment and prevention of severe decline are possible.”

– Nathan Jeffay, Times of Israel

MORE INFO

Neurosteer Wins Roche Alzheimer’s Innovation Challenge

Thu, 14 Jul 2022 16:48:52 GMT

And the winner in Roche and SNC’s Alzheimer’s Innovation Challenge is… Neurosteer, who has developed a solution designed for the early detection of a variety of neurological disorders. The solution aims to bring EEG tests to the patient’s home with a wearable device and a cloud-based system that together provide real-time monitoring and assessment of brain activity. The wearable, attached to the patient’s forehead, monitors cognitive and emotional activities. The information is gathered in the cloud, where it is being processed and assessed using AI and machine learning techniques. The insights are relayed to the patient and the care-giver in the form of neuro-feedback or alerts.

Neurosteer was one of 5 finalists in the challenge and will receive a prize of 100K NIS, a System Check (EU solution readiness check) by RoX Health, and mentorship with medical and business experts.

The challenge was launched by Roche and Start-Up Nation Central with the vision of enhanced digital health support for Alzheimer’s disease patients and their caregivers. The aim was to identify innovative solutions that will make a difference in patients’ lives.

Congratulations to the winning team!

– Startup Nation Central on behalf of Roche

MORE INFO

Brain Health – Company of the Year Award

Sun, 15 Dec 2019 20:48:00 GMT

Neurosteer received the “ Brain Health Company of the Year ” award from Tradex News . It has been a great year for us, most notably in improving our product for early screening of Alzheimer’s, Parkinson’s and fronto-temporal dementia.

The Effect of Music on Our Brain

Tue, 19 Nov 2019 21:25:00 GMT

Following recent fMRI studies on the effect of music on the brain, Israeli TV Channel 13 interviewed Neta Maimon , a PhD student in music cognition at Tel Aviv University and a researcher at Neurosteer. Using Neurosteer sensing technology on a group of brain-monitored study participants, emotional and cognitive responses to songs were clearly visible.

Monitoring Two Runners During the NYC Marathon

Sun, 03 Nov 2019 19:28:00 GMT

Neurosteer monitored two runners, in real time, during the NYC marathon on Nov 3rd. Prof. Steven Laureys, a key figure in the European Human Brain Project, was behind this initiative, which created significant interest in sports and other brain monitoring in extreme physical conditions. The article in DeMorgen describes it (in Dutch; use Google Translate). The full event was streamed live on Facebook . When going over the recording, one can see that Steven was meditating during much of the run (a well-known method to reduce oxygen consumption).

Monitoring and Assessing Surgeons at the ACS Conference

Wed, 30 Oct 2019 17:30:00 GMT

Neurosteer, together with Stanford Prof. Carla Pugh, is quantifying and assessing surgeon performance before and during surgery as part of the Stanford Surgical Metrics project. During the American College of Surgeons conference in San Fransisco, brain activity data from more than 200 surgeons was collected. Check out the video to see the cognitive assessment and monitoring during simulated surgery. This illustrates an application of Neurosteer’s platform for the evaluation of cognitive performance of healthy subjects. The same setup can be used to monitor pilots and others during critical missions.

Broadcast at Burdenko Institute in Moscow

Thu, 28 Feb 2019 08:23:00 GMT

Video of Neurosteer at the Burdenko Institute in Moscow.

Health Europa – Introducing a Novel Brain Activity Monitor

Tue, 20 Nov 2018 10:38:00 GMT

Neurosteer has developed a three-electrode neurological monitor that provides multiple brain activity biomarkers.

Neurosteer has the mission to improve the quality of brain disorder care by creating meaningful and easy-to-use brain activity measures that provide immediate neurofeedback as well as general brain activity assessment. The company produces high-level brain activity biomarkers in real time which enable treatment improvement by affordable and continuous monitoring of neural activity.

The mobile monitor can be used next to a hospital bed or at home and provides assessment and monitoring, with real-time alerts.

The Activity of the Brain

Automatic and accurate brain monitoring is key for optimised treatment both in the clinic and at home. For example, in the Intensive Care Unit (ICU), it can help prevent secondary trauma due to epilepsy or oedema, and in the operating room, it can reduce post-operative cognitive decline. Similarly, monitoring of home-care patients can indicate drug compliance and effectiveness, and provide a general indication of neural activity without the presence of a neurologist.

The current focus of Neurosteer is neurodegenerative diseases and mood disorders, as well as various forms of epilepsy, and the main effort is devoted to assisting with drug development and neurostimulation optimisation. For clinical trials and preventive medicine, Neurosteer can provide affordable patient screening and monitoring as well as quantification of the response to neurological and psychiatric drugs.

The system uses proprietary, real-time algorithms which run on the cloud and produce biomarkers that can be read using any web interface. The biomarkers are associated with various forms of cognitive load, emotional states, stress, pain, abnormal (epileptic) activity, disorders of consciousness, sleep stages and level of anaesthesia. Importantly, the biomarkers do not require electroencephalography (EEG) expert interpretation, thereby saving time and reducing costs. Objective statistics, trends and historical data are available for a single patient or a group of patients. The historical data can be easily integrated with other analytics tools used for better trial management.

About Neurosteer

Neurosteer’s core technology was developed at Tel Aviv University, Israel, by co-founder and CEO Nathan Intrator. Intrator received a PhD in applied mathematics from Brown University, US, and is a professor (on leave) of computer science and neuroscience at Tel Aviv University. He studied the signal-processing capabilities of sonar animals and developed signal-processing methods for brain activity interpretation and brain-computer interfaces, most notably for extensive information extraction from a single EEG channel. Neurosteer commercialises this technology to provide mobile brain analysis with medical and wellness applications.

Neurosteer has already helped a number of patients and their families – specifically, assisting caregivers in their assessment and providing a clear response to physical and other stimulation. In addition, the system is being used for assessment of Parkinson’s disease and frontotemporal dementia (FTD) patients. Moreover, the system provides indication of the response to transcranial direct current stimulation (tDCS) and deep brain stimulation (DBS).

MORE INFO

Compassion Meditation

Thu, 18 Oct 2018 08:35:00 GMT

Matthieu Ricard is one of the Buddhist monks that is most studied by Neuroscientists. His compassion meditation was contrasted with Indian breathing and mindfulness meditations by leading researchers. Matthieu joined Professor Steven Laureys for meditation and dialogue. Neurosteer monitored the brain activity during his compassion meditation, which looks very different from other meditations. We are excited to see a shift from multiple electrodes and fMRI to our single EEG channel.

Parkinson’s Assessment

Mon, 17 Sep 2018 08:34:00 GMT

The Parkinson Therapy Center in Brescia attracts patients from all over the world (many under 60) for a week of training to live with the disease. The neuropsychologists at the center are using Neurosteer’s frontal lobe cognitive assessment to suggest specific therapies to the different patients. Here is a short broadcast demonstrating this exciting project on Italian television.

Neurosteer in a tDCS Study at Langone Hospital

Mon, 20 Aug 2018 08:33:00 GMT

Neurosteer started a clinical study at Langone Hospital, NYU with Prof. Leigh Charvet, on quantifying the effect of tDCS on Multiple Sclerosis (MS) patients. MS patients receive a frontal lobe stimulation to improve their cognition. Such stimulation is not always effective, and often patients receive 20 stimulation sessions to discover at the end that there was no effect. Neurosteer’s device will assess the effectiveness of the stimulation after one session and this will be correlated with the effect after 20 sessions. Such an assessment can provide an indication of the effectiveness of the treatment.

Neurosteer at Stanford University

Thu, 15 Feb 2018 19:06:00 GMT

Neurosteer’s Nathan Intrator will discuss mobile brain sensing in clinical trials at the Neurotech conference at Stanford on February 26-27, 2018. Other speakers include DARPA’s Justin Sanchez; Kernel’s Bryan Johnson; Verily’s Brian Otis; Openwater’s Mary Lou Jepsen; and Khosla Ventures’ Vinod Khosla.

Prof. Steven Laureys Uses Neurosteer to Monitor Consciousness in Babies

Mon, 08 Jan 2018 18:19:00 GMT

Consciousness in Babies | Prof Steven Laureys | TEDxFlandersWomen

Neurosteer at the MIT Media Lab

Tue, 19 Sep 2017 15:45:00 GMT

Neurosteer’s Nathan Intrator on mobile brain sensing at the MIT Media Lab.

Version 3 is Here!

Thu, 03 Aug 2017 13:59:00 GMT

Neurosteer Exhibits at BIO in San Diego, Booth #2611

Tue, 20 Jun 2017 22:57:00 GMT

Visit Neurosteer at booth #2611, or hear the company presentation on June 21st in Theater 4 at 2pm .

Neurosteer Keynote at Moscow Yandex Conference

Sun, 18 Jun 2017 11:02:00 GMT

Nathan Intrator was a keynote speaker at yet another Conference by Yandex, May 30, 2017, Moscow.

Neurosteer Keynote at Stanford University

Thu, 01 Jun 2017 15:39:00 GMT

On February 7, 2017 at Stanford University , Nathan Intrator described Neurosteer at the Wearable Tech + Digital Health + Neurotech conference.

Neurosteer on StartUp Health NOW

Wed, 31 May 2017 08:24:00 GMT

Neurosteer’s Nathan Intrator on “Cracking the Code on Mobile Brain Monitoring” with StartUp Health’s Unity Stoakes.

Neurosteer Keynote at Moscow Yandex Conference

Tue, 30 May 2017 15:41:00 GMT

On May 30, 2017, Neurosteer CEO Nathan Intrator will keynote the Digital Health track of Yandex’s annual conference .

Ynet TV: Neurosteer’s Real-Time Measurement of Cognitive Load

Fri, 10 Jun 2016 19:54:00 GMT

http://www.ynet.co.il/video/0,20658,141298-4974311,00.html

Neurosteer’s Nathan Intrator interviewed by StartUp Health’s Steve Krein

Wed, 19 Aug 2015 08:20:00 GMT